The POPular PAUSE TAVI trial presented at the European Society of Cardiology Congress showed that continuing oral anticoagulant therapy during transcatheter aortic valve implantation (TAVI) did not provide any benefits and actually increased the risk of bleeding. The trial included 858 patients and indicated that interruption of anticoagulant therapy was superior to continuous therapy in terms of combined outcomes. While observational studies had suggested that continuing anticoagulants could decrease the risk of thrombotic events during TAVI, this trial showed no reduction in such events with continuous therapy. More research is needed to explore other possible strategies for managing anticoagulant therapy in patients undergoing TAVI.
Source link
Pause Anticoagulants During TAVI to Reduce Bleeding Risk
